[ Price : $8.95]
FDA commissioner Marty Makary tells Fox Business that the agency will deploy its new national priority voucher program to signific...[ Price : $8.95]
FDA approves Mercks Idvynso, a once-daily, single-tablet regimen for adults with HIV-1 who are already virologically suppressed.[ Price : $8.95]
Outlook Therapeutics completes a formal dispute resolution meeting with FDA as part of the companys push to revive its approval pr...[ Price : $8.95]
FDA outlines expanded efforts to reduce animal testing in drug development after reporting significant first-year progress under i...[ Price : $8.95]
President Trump signs an executive order aimed at accelerating the development and availability of psychedelic-based treatments fo...[ Price : $8.95]
FDA accepts for priority review a Pfizer and Astellas Pharma supplemental BLA for Padcev (enfortumab vedotin-ejfv) that seeks to ...[ Price : $8.95]
FDA updates a guidance clarifying how patients, physicians, and drug developers can access investigational therapies outside of cl...[ Price : $8.95]
Nektar Therapeutics reports new 52-week data from its mid-stage REZOLVE-AA trial, showing continued improvement in hair regrowth a...